Combining xQTL and genome‐wide association studies from ethnically diverse populations improves druggable gene discovery

Our findings underscore the power and efficiency of gene-based association testing, integrating multi-omic information as a strategic and efficient tool for informed drug target discovery and validation based on human genetic and genomic data for AD and AD-related dementia if broadly applied. These findings additionally highlight the limitations of standard inference based on detecting disease-associated SNPs in GWAS, for which there is generally significantly less power than in gene-based testing.